Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04439799 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections
A Phase 4 study of Hypogonadism, Male, sponsored by University of Miami.
- Completed
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT04439799: Completed Phase 4 study of Hypogonadism, Male, sponsored by University of Miami.
NCT04439799 is a Phase 4 study of Hypogonadism, Male that has completed, run by University of Miami. The registered enrollment target is 81 participants, below the 106-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04439799, a Phase 4 study of Hypogonadism, Male, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate changes in vascular parameters and the prevalence of side effects in subjects receiving 1 cc (200mg) every 2 weeks intramuscular (IM) of Testosterone Cypionate versus subjects receiving 11mg three times daily (TID) Natesto to participant with clinical hypogonadism.
Primary Outcome
Changes in serum Hematocrit levels will be assessed in percentage
Conditions Studied
Interventions
- DRUG Testosterone Cypionate 200 Mg/ML
- DRUG Intranasal Testosterone
Study Locations (1)
Florida
- University of Miami Miller School of Medicine - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2020-08-07 |
| Est. Completion | 2023-02-09 |
| Phase | Phase 4 |
What the finished NCT04439799 record still lists
NCT04439799 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 106-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (24% lower).
The record links to 1 condition, with Hypogonadism, Male appearing as the primary indexed condition, and to 2 interventions - of which Testosterone Cypionate 200 Mg/ML is the first listed.
NCT04439799 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04439799 about?
NCT04439799 is a clinical study titled "A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections". The purpose of this study is to evaluate changes in vascular parameters and the prevalence of side effects in subjects receiving 1 cc (200mg) every 2 weeks intramuscular (IM) of Testosterone Cypionate versus subjects receiving 11mg three times daily (TID) Natesto to participant with clinical hypogon...
What is the current status of trial NCT04439799?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2020-08-07. Estimated completion is 2023-02-09.
What conditions does trial NCT04439799 study?
This clinical trial studies the following conditions: Hypogonadism, Male.
What interventions are being tested in trial NCT04439799?
The interventions under investigation include: Testosterone Cypionate 200 Mg/ML (DRUG), Intranasal Testosterone (DRUG).
Who is sponsoring clinical trial NCT04439799?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04439799 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism, Male
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04439799's enrollment target sits among peer trials
81 8th of 12 higher than 5 of 12 other Hypogonadism, Male trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypogonadism, Male trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vogelxo(R) ABPM Study in Hypogandal Men
COMPLETED · Phase 4
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
-
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
RECRUITING · Phase 2
-
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
RECRUITING · Phase 3
-
Testosterone Treatment in Men with Chronic Kidney Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI